Official Title
Phase I/IIA Study of Descartes-30 in Acute Respiratory Distress Syndrome
Brief Summary

Emergency study to test the safety of Descartes-30 cells in patients with moderate-to-severe acute respiratory distress syndrome (ARDS) AND COVID-19

Recruiting
Acute Respiratory Distress Syndrome
COVID19

Biological: Descartes 30

Mesenchymal Stem Cells or MSCs RNA-engineered to secrete a combination of DNases.

Eligibility Criteria

Inclusion Criteria:

- Patients must be 18 years of age or older at the time of enrollment

- Patient maintains a diagnosis of moderate or severe ARDS according to the Berlin
definition of ARDS

Exclusion Criteria:

- Patient is currently enrolled into another therapeutic clinical trial with an
experimental therapy that has not received marketing approval by U.S. FDA.

- Patient is in moribund state with expected survival <24 hours.

Eligibility Gender
All
Eligibility Age
Minimum: 18 Years ~ Maximum: N/A
Countries
United States
Locations

University of Iowa Hospitals and Clinics
Iowa City, Iowa, United States

University of Maryland Medical Center Medical Center
Baltimore, Maryland, United States

Contacts

Hafsa Kamboh, MD
3013488698
trials@cartesiantx.com

Cartesian Therapeutics
NCT Number
MeSH Terms
Respiratory Distress Syndrome
Respiratory Distress Syndrome, Newborn
Acute Lung Injury
Syndrome